Drug Discovery Today: Technologies最新文献_第7页

Efficient molecular encoders for virtual screening 用于虚拟筛选的高效分子编码器

Drug Discovery Today: Technologies Pub Date : 2019-12-01 DOI: 10.1016/j.ddtec.2020.08.004

Youjun Xu , Chenjing Cai , Shiwei Wang , Luhua Lai , Jianfeng Pei

引用次数: 3

The art of atom descriptor design 原子描述符设计的艺术

Drug Discovery Today: Technologies Pub Date : 2019-12-01 DOI: 10.1016/j.ddtec.2020.06.004

Andreas H. Göller

引用次数: 4

Graph-based generative models for de Novo drug design 基于图的新生药物设计生成模型

Drug Discovery Today: Technologies Pub Date : 2019-12-01 DOI: 10.1016/j.ddtec.2020.11.004

Xiaolin Xia, Jianxing Hu, Yanxing Wang, Liangren Zhang, Zhenming Liu

引用次数: 19

Recent advancements in DVD-Ig based therapeutic development 基于DVD-Ig的治疗发展的最新进展

Drug Discovery Today: Technologies Pub Date : 2019-12-01 DOI: 10.1016/j.ddtec.2020.10.002

Feng Dong, Tariq Ghayur

引用次数: 2

Editorial for the Special Section "Artificial Intelligence in Drug Discovery" “药物发现中的人工智能”专区社论

Drug Discovery Today: Technologies Pub Date : 2019-12-01 DOI: 10.1016/j.ddtec.2020.12.001

Johannes Kirchmair

引用次数: 0

The good, the bad, and the ugly in chemical and biological data for machine learning 机器学习中化学和生物数据的优点、缺点和缺点。

Drug Discovery Today: Technologies Pub Date : 2019-12-01 DOI: 10.1016/j.ddtec.2020.07.001

Tiago Rodrigues

引用次数: 19

Liver targeted gene therapy: Insights into emerging therapies 肝脏靶向基因治疗:对新兴疗法的见解

Drug Discovery Today: Technologies Pub Date : 2019-12-01 DOI: 10.1016/j.ddtec.2020.11.001

Carlos G. Moscoso , Clifford J. Steer

{"title":"Liver targeted gene therapy: Insights into emerging therapies","authors":"Carlos G. Moscoso , Clifford J. Steer","doi":"10.1016/j.ddtec.2020.11.001","DOIUrl":"10.1016/j.ddtec.2020.11.001","url":null,"abstract":"<div>The large number of monogenic metabolic disorders originating in the liver poses a unique opportunity for development of gene therapy modalities to pursue curative approaches. Various disorders have been successfully treated via liver-directed gene therapy, though most of the advances have been in animal models, with only limited success in clinical trials. Pre-clinical data in animals using non-viral approaches, including the Sleeping Beauty transposon system, are discussed. The various advances with viral vectors for liver-directed gene therapy are also a focus of this review, including retroviral, adenoviral, recombinant adeno-associated viral, and SV40 vectors. Genome editing techniques, including zinc finger nucleases, transcription activator-like effector nucleases and clustered regularly interspaced short palindromic repeats (CRISPR), are also described. Further, the various controversies in the field with regards to somatic vs. germline editing using CRISPR in humans are explored, while also highlighting the myriad of preclinical advances. Lastly, newer technologies are reviewed, including base editing and prime editing, which use CRISPR with exciting adjunctive properties to avoid double-stranded breaks and thus the recruitment of endogenous repair mechanisms. While encouraging results have been achieved recently, there are still significant challenges to overcome prior to the broad use of vector-based and genome editing techniques in the clinical arena. As these technologies mature, the promise of a cure for many disabling inherited metabolic disorders is within reach, and urgently needed.</div>","PeriodicalId":36012,"journal":{"name":"Drug Discovery Today: Technologies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ddtec.2020.11.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38747316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Current methods and challenges for deep learning in drug discovery 药物发现中深度学习的当前方法和挑战

Drug Discovery Today: Technologies Pub Date : 2019-12-01 DOI: 10.1016/j.ddtec.2020.07.003

Stefan Schroedl

引用次数: 9

Structurally-defined deubiquitinase inhibitors provide opportunities to investigate disease mechanisms 结构明确的去泛素酶抑制剂为研究疾病机制提供了机会

Drug Discovery Today: Technologies Pub Date : 2019-04-01 DOI: 10.1016/j.ddtec.2019.02.003

Ingrid E. Wertz , Jeremy M. Murray

{"title":"Structurally-defined deubiquitinase inhibitors provide opportunities to investigate disease mechanisms","authors":"Ingrid E. Wertz , Jeremy M. Murray","doi":"10.1016/j.ddtec.2019.02.003","DOIUrl":"10.1016/j.ddtec.2019.02.003","url":null,"abstract":"<div>The Ubiquitin/Proteasome System comprises an essential cellular mechanism for regulated protein degradation. Ubiquitination may also promote the assembly of protein complexes that initiate intracellular signaling cascades. Thus, proper regulation of substrate protein ubiquitination is essential for maintaining normal cellular physiology. Deubiquitinases are the class of enzymes responsible for removing ubiquitin modifications from target proteins and have been implicated in regulating human disease. As such, deubiquitinases are now recognized as emerging drug targets. Small molecule deubiquitinase inhibitors have been developed; among those, inhibitors for the deubiquitinases USP7 and USP14 are the best-characterized given that they are structurally validated. In this review we discuss the normal physiological roles of the USP7 and USP14 deubiquitinases as well as the pathological conditions associated with their dysfunction, with a focus on oncology and neurodegenerative diseases. We also review structural biology of USP7 and USP14 enzymes and the characterization of their respective inhibitors, highlighting the various molecular mechanisms by which these deubiquitinases may be functionally inhibited. Finally, we summarize the cellular and in vivo studies performed using the structurally-validated USP7 and USP14 inhibitors.</div>","PeriodicalId":36012,"journal":{"name":"Drug Discovery Today: Technologies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ddtec.2019.02.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37330623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 35

Protein degradation for drug discovery 蛋白质降解用于药物发现

Drug Discovery Today: Technologies Pub Date : 2019-04-01 DOI: 10.1016/j.ddtec.2019.04.002

Alessio Ciulli, William Farnaby

引用次数: 10